• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Latest News

Featured News

Scancell Receives UK MHRA Clinical Trial Authorization for Phase 3 Registrational Trial of iSCIB1+ in Advanced Melanoma

Aug 19, 2026

Select the category

  • All categories
  • Covid-19
  • GlyMab
  • Immunobody
  • Interviews
  • iSCIB1+
  • Latest News
  • Media Coverage
  • Modi-1
  • Modi-2
  • Moditope
  • News
  • Presentations
  • Regulatory News
  • SCIB1

Select the year

  • All years
  • 2022
  • 2023
  • 2024
  • 2025
  • 2026
Clear Filters
U

Notice of Interim Results and Investor Presentation

January 22, 2026

Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+

December 9, 2025

Scancell to present positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025

November 7, 2025

Results of 2025 Annual General Meeting

October 30, 2025

Notice of Annual General Meeting

October 3, 2025

Director Dealing

September 16, 2025
  • 4
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 5
No results found.

Regulatory News Archive

View archive

JOIN OUR MAILING LIST

Sign up for news updates to stay up to date with Scancell.

    Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

    • Follow
    • Follow

    Science
    Our Pipeline
    News
    Contact Us
    Find a Trial
    Become an Investigator

    ACTIVE IMMUNOTHERAPY

    ImmunoBody®
    Moditope®

    ANTIBODIES

    GlyMab®
    AvidiMab®

    Investors
    Company Profile
    Advisors
    Corporate Governance
    Documents & Presentations
    Share Information
    Financial Information

    Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy